Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12653103 | 0.88 | MEN1 (0.57) | TRPV1KDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL12359235 | 0.88 | TRPV1 (0.54) | TRPV1KDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL12359288 | 0.86 | TRPV1 (0.46) | TRPV1KDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL12358823 | 0.84 | TRPV1 (0.44) | TRPV1KDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL12350046 | 0.81 | TRPV1 (0.52) | TRPV1KDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL1799694 | 0.81 | TRPV1 (0.61) | TRPV1KDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL1799365 | 0.81 | TRPV1 (0.70) | TRPV1 | |
| SCHEMBL1799697 | 0.81 | TRPV1 (0.61) | TRPV1KDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL1799363 | 0.81 | TRPV1 (0.70) | TRPV1 | |
| SCHEMBL12359287 | 0.80 | NPC1 (0.48) | TRPV1KDM4EMEN1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885KDM4E 2796/4885MEN1 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.